Literature DB >> 29662562

The Predictive Values of Lesion Size, F-18 FDG Avidity and I-131 Avidity for the Clinical Outcome of I-131 Treatment in Patients with Metastatic Differentiated Thyroid Carcinoma Only in the Lung.

Joon Ho Choi1, Byung Hyun Byun1, Ilhan Lim1, Hansol Moon1, Jihyun Park1, Kyoung Jin Chang1, Byung Il Kim1, Chang Woon Choi1, Sang Moo Lim1.   

Abstract

PURPOSE: We aimed to evaluate the prognostic values of radiography, F-18 FDG PET, and I-131 whole body scans in patients with lung-only metastasis from differentiated thyroid carcinoma (DTC).
METHODS: Between 1998 and 2013, we included 31 patients (F: 26, M: 5) with lung-only metastasis from DTC who had been treated with I-131 and underwent PET. Lung metastasis was categorized according to the size (macronodular ≥1.0 cm vs. micronodular <1.0 cm), FDG avidity (avid vs. non-avid), and I-131 avidity (avid vs. non-avid). Progression-free survival (PFS) was evaluated for each patient.
RESULTS: Among 31 patients, seven (23%) had macronodular lung metastasis, 26 (84%) had FDG avid lung metastasis, and 16 (52%) had I-131 avid lung metastasis. During the median follow-up period of 9.4 y, median PFS was 6.1 y. Based on Kaplan-Meier analysis, macronodular lung metastasis (p = 0.017) and I-131 non-avid lung metastasis (p = 0.059) were significantly associated with worse outcomes, but FDG avid lung metastasis was not (p = 0.135). Patients with FDG non-avid lung metastasis did not experience disease progression during follow-up, while 11 of 26 patients (42%) experienced disease progression. Based on univariate analysis, the hazard ratio for a poor prognosis was 3.78 (p = 0.029) for macronodular lung metastasis and 3.29 (p = 0.079) for I-131 non-avid lung metastasis.
CONCLUSIONS: Macronodular and I-131 non-avid lung metastasis were associated with a poor prognosis in lung-only metastasis from DTC. Although FDG avid lung metastasis may be associated with a poor prognosis, a larger-scale study is needed.

Entities:  

Keywords:  Differentiated thyroid carcinoma; F-18 FDG avidity; I-131 avidity; Lung metastasis; Macronodular; Micronodular

Year:  2017        PMID: 29662562      PMCID: PMC5897259          DOI: 10.1007/s13139-017-0502-9

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  24 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

2.  Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.

Authors:  W Wang; S M Larson; M Fazzari; S K Tickoo; K Kolbert; G Sgouros; H Yeung; H Macapinlac; J Rosai; R J Robbins
Journal:  J Clin Endocrinol Metab       Date:  2000-03       Impact factor: 5.958

3.  Long-term survival and low effective cumulative radioiodine doses to achieve remission in patients with 131Iodine-avid lung metastasis from differentiated thyroid cancer.

Authors:  Fabián Pitoia; Fernanda Bueno; Graciela Cross
Journal:  Clin Nucl Med       Date:  2014-09       Impact factor: 7.794

Review 4.  Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project.

Authors:  Thierry Berghmans; Michèle Dusart; Marianne Paesmans; Claude Hossein-Foucher; Irene Buvat; Catherine Castaigne; Arnaud Scherpereel; Céline Mascaux; Michel Moreau; Martine Roelandts; Stéphane Alard; Anne-Pascale Meert; Edward F Patz; Jean-Jacques Lafitte; Jean-Paul Sculier
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

5.  Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine.

Authors:  F Pacini; F Cetani; P Miccoli; F Mancusi; C Ceccarelli; F Lippi; E Martino; A Pinchera
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

6.  Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis.

Authors:  Elliot Sampson; James D Brierley; Lisa W Le; Lorne Rotstein; Richard W Tsang
Journal:  Cancer       Date:  2007-10-01       Impact factor: 6.860

7.  Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake.

Authors:  C M Hong; B-C Ahn; S Y Jeong; S-W Lee; J Lee
Journal:  Nuklearmedizin       Date:  2013       Impact factor: 1.379

8.  Prognostic value of pretreatment standardized uptake value of F-18-fluorodeoxyglucose PET in patients with gastric cancer: a meta-analysis.

Authors:  Zhonghua Wu; Junhua Zhao; Peng Gao; Yongxi Song; Jingxu Sun; Xiaowan Chen; Bin Ma; Zhenning Wang
Journal:  BMC Cancer       Date:  2017-04-17       Impact factor: 4.430

9.  Evaluating the prognostic factors associated with cancer-specific survival of differentiated thyroid carcinoma presenting with distant metastasis.

Authors:  Brian Hung-Hin Lang; Kai Pun Wong; Chung Yeung Cheung; Koon Yat Wan; Chung-Yau Lo
Journal:  Ann Surg Oncol       Date:  2012-10-28       Impact factor: 5.344

10.  Distant metastases in differentiated thyroid cancer: long-term results of radioiodine treatment and statistical analysis of prognostic factors in 214 patients.

Authors:  D Casara; D Rubello; G Saladini; V Gallo; G Masarotto; B Busnardo
Journal:  Tumori       Date:  1991-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.